Search
Lapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalIt binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesSynonyms: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamineHexoprenaline
go.drugbank.com/drugs/DB08957ApprovedWithdrawnHexoprenaline is a stimulant of beta 2 adrenergic receptors. It is used as a bronchodilator, antiasthmatic, and tocolytic agent.
Products: Gynipral 10 µg/2 ml - Ampullen, Gynipral 25 µg - Konzentrat zur InfusionsbereitungCarmoterol
go.drugbank.com/drugs/DB15784InvestigationalMixtures: LUXNID 2/200 MCG INHALASYON IÇIN TOZ IÇIEREN KAPSÜL,60 KAPSÜL, LUXNID 2/400 MCG INHALASYON IÇIN TOZ IÇEREN BLISTER ,60 DOZProducts: AIRWAY 1 MCG INHALASYON IÇIN TOZ IÇEREN BLISTER, 60 DOZ, AIRWAY 2 MCG INHALASYON IÇIN TOZ IÇEREN BLISTER, 60 DOZButenafine
go.drugbank.com/drugs/DB01091ApprovedButenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. … In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.
Products: BUTAFLY % 1 LOSYON ,10 ML, BUTEFIN %1 KREM, 30 GTeduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalThe significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012. … Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine).
Products: REVESTIVE® 5 MGAllergy to vaccine
go.drugbank.com/conditions/DBCOND0013625Drugs: ChlorpheniramineSynonyms: Allergy to vaccine, Allergy to component of vaccine productSulfinpyrazone
go.drugbank.com/drugs/DB01138ApprovedA uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesProducts: ยาเม็ดซัลฟิน 100 มิลลิกรัม, Sulfinpyrazone 100 TabElosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalThe recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week. … It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.
Products: Vimizim 1mg/ml Concentrate for Solution for Infusion, VIMIZIM® 1MG/ML SOLUCIÓN CONCENTRADA PARA INFUSIÓNDichloroacetic acid
go.drugbank.com/drugs/DB08809ApprovedInvestigationalWithdrawnA phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness. … Dichloroacetic acid, often abbreviated DCA, is an acid analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms.
Products: Bichloracetic Acid 100%Gilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. … [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: XOSPATA 40 MG FİLM KAPLI TABLET, 84 ADET